<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="HACEC994D96B94CECBFE8332AD82EF72A" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>118 HR 1758 IH: Stopping Illicit Fentanyl Trafficking Act of 2023</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2023-03-23</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">118th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 1758</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20230323">March 23, 2023</action-date><action-desc><sponsor name-id="L000569">Mr. Luetkemeyer</sponsor> (for himself, <cosponsor name-id="H001091">Mrs. Hinson</cosponsor>, <cosponsor name-id="B001298">Mr. Bacon</cosponsor>, <cosponsor name-id="D000616">Mr. DesJarlais</cosponsor>, and <cosponsor name-id="E000235">Mr. Ezell</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name>, and in addition to the Committee on <committee-name committee-id="HJU00">the Judiciary</committee-name>, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned</action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To amend the Controlled Substances Act to list fentanyl-related substances as schedule I controlled substances.</official-title></form><legis-body id="H90D3FFB929D94514B0C671C28CEBEAD4" style="OLC"><section id="HA306123F01094C5080B30DFEC15A1FFA" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Stopping Illicit Fentanyl Trafficking Act of 2023</short-title></quote> or the <quote><short-title>SIFT Act of 2023</short-title></quote>.</text></section><section id="HB8E6863238F046FBAA5D2E6185728655"><enum>2.</enum><header>Fentanyl-related substances</header><text display-inline="no-display-inline">Section 202(c) of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/812">21 U.S.C. 812</external-xref>) is amended—</text><paragraph id="H6CE6EE751C314843BA8010987209F7E4"><enum>(1)</enum><text>by adding at the end of subsection (b) of Schedule I the following:</text><quoted-block id="HCD57DCE61EB8431EBA3FA315DE4A49A9" style="OLC"><paragraph id="H1244BAB2A4814AD49AA4C11946B26B69"><enum>(23)</enum><text>Isobutyryl fentanyl.</text></paragraph><paragraph id="H408D1A1B2E734202AEF5FA4C8D641718"><enum>(24)</enum><text>Para-Methoxybutyrylfentanyl.</text></paragraph><paragraph id="HFE23C2F8C8C44AA6B8C95A5A817425F0"><enum>(25)</enum><text>Valeryl fentanyl.</text></paragraph><paragraph id="H60699BCCD1FE4AE5ACB9BC2A9EA0F3C2"><enum>(26)</enum><text>Cyclopentyl fentanyl.</text></paragraph><paragraph id="H809219AA770F47A791EEB51912280AA3"><enum>(27)</enum><text>Para-Chloroisobutyryl fentanyl.</text></paragraph><after-quoted-block>; and</after-quoted-block></quoted-block></paragraph><paragraph id="HF44B9692C8C24D9E88DFF27E064C59D7"><enum>(2)</enum><text>by adding at the end of Schedule I the following:</text><quoted-block id="H2A812A1D175048B4854A138B0289F520" style="OLC"><subsection id="H70345DFB8A474E958E5513879FFC5643"><enum>(e)</enum><paragraph commented="no" display-inline="yes-display-inline" id="H71C306B8256644939830459517CC7980"><enum>(1)</enum><text>Unless specifically exempted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of fentanyl-related substances, or which contains their salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation.</text></paragraph><paragraph id="H2E60D7DB89D7409090714BDA88F82C33" indent="up1"><enum>(2)</enum><text>In paragraph (1), the term <term>fentanyl-related substances</term> includes the following:</text><subparagraph id="HF5C6024B03E044CCB7C74C1B6F15D7CA"><enum>(A)</enum><text>Any substance that is structurally related to fentanyl by one or more of the following modifications:</text><clause id="H4564B53EAA904180B3940DFB5F9ECFA4"><enum>(i)</enum><text>By replacement of the phenyl portion of the phenethyl group by any monocycle, whether or not further substituted in or on the monocycle.</text></clause><clause id="HBCA0BD965CE84D8DA1A2D1221E83B884"><enum>(ii)</enum><text>By substitution in or on the phenethyl group with alkyl, alkenyl, alkoxy, hydroxy, halo, haloalkyl, amino or nitro groups.</text></clause><clause id="H3582C16C7C3B41AF814075949ABC20F9"><enum>(iii)</enum><text>By substitution in or on the piperidine ring with alkyl, alkenyl, alkoxy, ester, ether, hydroxy, halo, haloalkyl, amino or nitro groups.</text></clause><clause id="HB3381977468D4A979465190A87E6CD5D"><enum>(iv)</enum><text>By replacement of the aniline ring with any aromatic monocycle whether or not further substituted in or on the aromatic monocycle.</text></clause><clause id="H812D8D7A977242C2A40DEF5360C3EC89"><enum>(v)</enum><text>By replacement of the N-propionyl group by another acyl group.</text></clause></subparagraph><subparagraph id="H3F5DE1BFCA2345B283E2FD5C664E9558"><enum>(B)</enum><text>4′-Methyl acetyl fentanyl.</text></subparagraph><subparagraph id="H0F6B7A9F465F4F99B79B1184219F1F75"><enum>(C)</enum><text>Crotonyl fentanyl.</text></subparagraph><subparagraph id="H34C3E6B5B5274C3AB0B39DC0E2955935"><enum>(D)</enum><text>2′-Fluoro ortho-fluorofentanyl.</text></subparagraph><subparagraph id="H7C51FACDF52C4051AB30BAF9D17CF7DA"><enum>(E)</enum><text>Ortho-Methyl acetylfentanyl.</text></subparagraph><subparagraph id="H8F39527B5E9345639B027E3ED8D06B4C"><enum>(F)</enum><text>Thiofuranyl fentanyl.</text></subparagraph><subparagraph id="H145C440ECF554F0BA93AEB66FAB86096"><enum>(G)</enum><text>Ortho-Fluorobutyryl fentanyl.</text></subparagraph><subparagraph id="HAFC1017F6825491EA10AEBD3FD6B2FB9"><enum>(H)</enum><text>Ortho-Fluoroacryl fentanyl.</text></subparagraph><subparagraph id="H56DF9FC0658443E08AC848DDEC868D04"><enum>(I)</enum><text>Beta-Methyl fentanyl.</text></subparagraph><subparagraph id="HBCAF744A644E4F6D8B3C835E4C1D77EE"><enum>(J)</enum><text>Phenyl fentanyl.</text></subparagraph><subparagraph id="H73A067D87A45431C9C5FB5983ACEECC0"><enum>(K)</enum><text>Para-Methylfentanyl.</text></subparagraph><subparagraph id="HD7AB3B08AFDE474AB87A98EE29308E11"><enum>(L)</enum><text>Beta′-Phenyl fentanyl.</text></subparagraph><subparagraph id="H9F0B47EAF2A44889A024D08907D4B7C3"><enum>(M)</enum><text>Benzodioxole fentanyl.</text></subparagraph></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></section><section id="HD6D8076094DD4E32B60169113D18DFB1"><enum>3.</enum><header>Removal from schedule I<enum-in-header>(e)</enum-in-header> of fentanyl-related substances</header><text display-inline="no-display-inline">Section 201 of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/811">21 U.S.C. 811</external-xref>) is amended by adding at the end the following new subsection:</text><quoted-block id="HF16D4C95834546A28E9B0903D8D5C737" style="OLC"><subsection id="HF55D1BE949294443A2843C305A8D8B8A"><enum>(k)</enum><paragraph commented="no" display-inline="yes-display-inline" id="H4C91395A4CD24B2C90A2B181344F6279"><enum>(1)</enum><text>If the Secretary finds, based on the factors specified in paragraph (4), that a substance listed in schedule I(e) has no potential for abuse, the Secretary shall—</text><subparagraph id="H32EA18DED4CA4E4C8EDFD5139A0C662C" indent="up1"><enum>(A)</enum><text display-inline="yes-display-inline">notify the Attorney General at least 90 days prior to submitting an evaluation scientific and medical evaluation of that substance supporting that conclusion; and</text></subparagraph><subparagraph id="H7F7E6C72534E44DFBFFDB4D0E59EE6A6" indent="up1"><enum>(B)</enum><text>submit to the Attorney General such evaluation and conclusion that—</text><clause id="H554451319E1E47ED937EFBA5899258FD"><enum>(i)</enum><text>is in writing; and</text></clause><clause id="H71123D4E9E99452A98002B136D3B06B5"><enum>(ii)</enum><text>includes the bases for such conclusion.</text></clause></subparagraph></paragraph><paragraph id="H52F1A5125BAF46CF8F70C4DAD0099D4D" indent="up1"><enum>(2)</enum><text>Not later than 90 days after the receipt of such evaluation and conclusion, the Attorney General shall issue an order removing such substance from the schedule.</text></paragraph><paragraph id="H160BF108ED12421B89540C25641B9F89" indent="up1"><enum>(3)</enum><subparagraph commented="no" display-inline="yes-display-inline" id="HBC00739BA9A54D7197105A4C6A1715F1"><enum>(A)</enum><text>If the Secretary finds, based on the factors specified in paragraph (4), that a substance listed in schedule I(e) does not meet the requirements for inclusion in that schedule, and that the substance has a low potential for abuse, the Secretary shall submit to the Attorney General a scientific and medical evaluation of that substance supporting those conclusions that is in writing and that includes the bases for that conclusion.</text></subparagraph><subparagraph id="H273D37933BAA4C62B3D3480AAAA74B06" indent="up1"><enum>(B)</enum><text>Within 180 days of receipt of such evaluation and conclusion, the Attorney General shall—</text><clause id="HEE1F1429B84F44B2B97EA7713A35BB2E"><enum>(i)</enum><text>issue an order removing such substance from scheduling for research purposes only; or</text></clause><clause id="H2C0CE2292E0D4F81A13536DDE71ABB65"><enum>(ii)</enum><text>notify the Secretary in writing that the Attorney General declines to issue such an order.</text></clause></subparagraph></paragraph><paragraph id="H1DC1B3BBEA054FD5B2AD03556A690626" indent="up1"><enum>(4)</enum><text>In making the evaluation and conclusion described in paragraph (1) or (3), the Secretary—</text><subparagraph id="H34DD5798DDFA40FC8FE665AFB8335683"><enum>(A)</enum><text>shall consider the factors specified in paragraphs (1), (2), (3), and (6) of subsection (c) and any information submitted to the Attorney General under paragraph (1) of this subsection; and</text></subparagraph><subparagraph id="HDF899CBC0B4046FBAAEFB4AB381E114A"><enum>(B)</enum><text>may also consider factors specified in paragraphs (4), (5), and (7) of subsection (c) if the Secretary finds that reliable evidence exists with respect to such factors.</text></subparagraph></paragraph><paragraph id="HF5D85DD980AB40B396F63EDCC695CD70" indent="up1"><enum>(5)</enum><text>Nothing in this subsection shall preclude the Attorney General from transferring a substance listed in schedule I to another schedule, or removing such substance entirely from the schedules, pursuant to other provisions of this section or section 202.</text></paragraph><paragraph id="H58C5A226363243A19AE89D6F1C377D81" indent="up1"><enum>(6)</enum><text display-inline="yes-display-inline">A substance removed from schedule I(e) pursuant to paragraph (1) or (3) may, at any time, be controlled pursuant to the other provisions of this section or section 202 without regard to that removal.</text></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block></section><section id="H0675125280674772BF78486B6F28FAED"><enum>4.</enum><header>Clarification of certain registration requirements related to research</header><subsection id="HECD9AC7945814A789B97DE99AE2A3718"><enum>(a)</enum><header>Exception for agents or employees of registered researchers</header><text>Section 302(c)(1) of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/822">21 U.S.C. 822(c)(1)</external-xref>) is amended by striking <quote>or dispenser</quote> and inserting <quote>dispenser, or researcher</quote>.</text></subsection><subsection id="HDEFA100D377245AC88F3BED4382321B1"><enum>(b)</enum><header>Conforming amendment</header><text>Section 102(3) of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/802">21 U.S.C. 802(3)</external-xref>) is amended by striking <quote>or dispenser</quote> and inserting <quote>dispenser, or researcher</quote>.</text></subsection><subsection id="H4C02CB1F190243EA902064E473C2EC24"><enum>(c)</enum><header>Single registration for contiguous research sites</header><text>Section 302(e) of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/822">21 U.S.C. 822(e)</external-xref>) is amended by adding at the end the following new paragraph:</text><quoted-block id="HEEF9E469ABD8424F97523B75012991B5" style="OLC"><paragraph id="H6FE27D22239E46E2B61B61FA8C124F98" indent="up1"><enum>(3)</enum><text>Notwithstanding paragraph (1), a person registered to conduct research with a controlled substance under section 303(f) may conduct such research under a single registration if such research occurs exclusively on a single, contiguous campus and the registrant notifies the Attorney General in writing of all sites on the campus where the research will be conducted or where the controlled substance will be stored or administered. If the registrant seeks to conduct such research at additional sites, the registrant shall submit a new notification before conducting such research at any such additional sites.</text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></subsection><subsection id="H788D208C018C4801A40652E89887ACF4"><enum>(d)</enum><header>New inspection not required in certain situations</header><text>Section 303(f) of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/823">21 U.S.C. 823(f)</external-xref>) is amended—</text><paragraph id="H3F6CF73914D04690B7A7AD49C34ECB43"><enum>(1)</enum><text>by redesignating paragraphs (1) through (5) as subparagraphs (A) through (E), respectively, and by moving the margins of such subparagraphs (as so redesignated) two ems to the right; </text></paragraph><paragraph id="HFB68C1F8A8A940F3968F8C0ABEE99961"><enum>(2)</enum><text>by striking <quote>(f) The</quote> and inserting <quote>(f)(1) The</quote>; and</text></paragraph><paragraph id="H9E67E871932145B98AF4D49D852F6C8D"><enum>(3)</enum><text>by adding at the end the following new paragraph:</text><quoted-block id="HB47A1356929E458A94663CEC5791818C" style="OLC"><paragraph id="HC14A95F9DAEE4FEE8D5BF742A5D3982C" indent="up1"><enum>(2)</enum><subparagraph commented="no" display-inline="yes-display-inline" id="H1AA1580AD4DD46F393DE4943AB153946"><enum>(A)</enum><text>If a person is registered to conduct research with a controlled substance and applies to be registered, or to modify a registration to conduct research with a second controlled substance that is in the same schedule or in a schedule with a higher numerical designation, a new inspection by the Attorney General of the registered location is not required.</text></subparagraph><subparagraph id="H0D8871857F7843B4803C6290245D0A99" indent="up1"><enum>(B)</enum><text>Nothing in this paragraph shall prohibit the Attorney General from conducting any inspection if the Attorney General determines such an inspection is necessary.</text></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection><subsection id="H824EE8B3BFAD4A1D803A687C12554950"><enum>(e)</enum><header>Continuation of research on newly added substances; authority To conduct research with other substances</header><text display-inline="yes-display-inline">Section 302 of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/822">21 U.S.C. 822</external-xref>), as amended by subsections (a) and (c), is further amended by adding at the end the following new subsection:</text><quoted-block id="H4C918B66F1DD4440854E06F176BF3B31" style="OLC"><subsection id="H2C52D13CFC754946B2477E3640855180"><enum>(h)</enum><paragraph commented="no" display-inline="yes-display-inline" id="H1B9A8C6BD3EA425D9D66EFE3F265C2E3"><enum>(1)</enum><text>In the case of a person who is conducting research on a substance at the time the substance is added to schedule I and who is already registered to conduct research with another controlled substance in schedule I or II, the person—</text><subparagraph id="H9849B4B1B1F84E0D8C51853C81711123" indent="up1"><enum>(A)</enum><text>within 30 days of the scheduling of such substance, shall submit a completed application for registration or modification of the existing registration of such person, to conduct research on such substance, in accordance with the regulations issued by the Attorney General; and</text></subparagraph><subparagraph id="HD356EC299C924E86A16CA480D870BBCA" indent="up1"><enum>(B)</enum><text>notwithstanding subsections (a) and (b), may continue to conduct the research on such substance until the date on which—</text><clause id="HD480D03ED64F4556BA1BCA90C6F634F5"><enum>(i)</enum><text>the application referred to in subparagraph (A) is withdrawn by the applicant; or</text></clause><clause id="H84B3A5B2C2DC42CD83C2D1A125B6C4CF"><enum>(ii)</enum><text>the Attorney General serves on the applicant an order to show cause proposing the denial of the application pursuant to section 304(c).</text></clause></subparagraph></paragraph><paragraph id="H515C2653B20E4B9E9D7461528F722B76" indent="up1"><enum>(2)</enum><text>If the Attorney General serves an order to show cause under paragraph (1)(B) and the applicant requests a hearing, such hearing shall be held—</text><subparagraph id="H44B793DC83754F1A87B23670BEC0BDC9"><enum>(A)</enum><text>on an expedited basis; and</text></subparagraph><subparagraph id="HECDAA8AF39584E2E93B137F1E2226965"><enum>(B)</enum><text>not later than 45 days after the request is made, or such a later time as requested by the applicant.</text></subparagraph></paragraph><paragraph id="H1A0B0BFA3C8741A2889BB99A870E408B" indent="up1"><enum>(3)</enum><subparagraph commented="no" display-inline="yes-display-inline" id="H9C099E5D7EC74D3497DDAC56CE601029"><enum>(A)</enum><text>A person who is registered to conduct research with a controlled substance in schedule I may, notwithstanding subsections (a) and (b), conduct research with another controlled substance in schedule I, if each of following conditions are met:</text><clause id="H5A97C0F950384AE68ECBB5EF6F356E9A" indent="up1"><enum>(i)</enum><text>The person has applied for a modification of the person’s registration to authorize research with such other controlled substance in accordance with the regulations issued by the Attorney General.</text></clause><clause id="H49B6A6D671C84087B6FF5E3F9072BB0C" indent="up1"><enum>(ii)</enum><text>The Attorney General has obtained verification from the Secretary that the research protocol submitted with the application is meritorious.</text></clause><clause id="H30D2FCFCEC74454FB6D0D2AEDB3A0BDF" indent="up1"><enum>(iii)</enum><text>The Attorney General has determined under subparagraph (B) that the conduct of such research is consistent with United States obligations under the Single Convention on Narcotic Drugs, 1961.</text></clause></subparagraph><subparagraph id="H1A4412AD4896456F9FA9653FAB21EC40" indent="up1"><enum>(B)</enum><text display-inline="yes-display-inline">Not later than 30 days after receiving an application under clause (i), the Attorney General shall determine whether the conduct of research that is the subject of the application is consistent with United States obligations under the Single Convention on Narcotic Drugs, 1961.</text></subparagraph><subparagraph id="HE6FCD9E4C72E4C3A9CE8F04B95C8663E" indent="up1"><enum>(C)</enum><text>Nothing in this section shall be construed to alter the authority of the Attorney General to initiate proceedings to deny, suspend, or revoke any registration in accordance with sections 303 and 304.</text></subparagraph></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block></subsection><subsection id="H794410118FBA46F0A53EB9A2AA1EE93D"><enum>(f)</enum><header>Treatment of certain activities as coincident to research</header><text display-inline="yes-display-inline">Section 302 of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/822">21 U.S.C. 822</external-xref>), as amended by subsections (a), (c), and (e), is further amended by adding at the end the following new subsection:</text><quoted-block id="H563E11C20ACE4F01B679E1E7DA309D2B" style="OLC"><subsection id="H73E19C6361EA47BA913E324B29442EE7"><enum>(i)</enum><text display-inline="yes-display-inline">A person who is registered to perform research with a controlled substance (other than marihuana) under this title may, without being required to registered to manufacture such substance, using small quantities of such substance, perform the following activities:</text><paragraph id="HDF303602DD954F818C72C438FC4B00E5"><enum>(1)</enum><text>Processing the substance to create extracts, tinctures, oils, solutions, derivatives, or other forms of the substance consistent with the approved research protocol.</text></paragraph><paragraph id="HE4C3A12F34D148B0AFF2D3FF18D86B71"><enum>(2)</enum><text>Dosage form development for the purpose of satisfying requirements with respect to the submission of an investigational new drug application under section 505(i) of the Federal Food, Drug, and Cosmetic Act.</text></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block></subsection></section><section id="HFB28D554A06C417D9595C632BF05083E"><enum>5.</enum><header>Review of research registration process</header><subsection id="HF20AE65F7386492EBCCF0F435B9F1848"><enum>(a)</enum><header>Review</header><text>Not later than one year after the date of the enactment of this section, the Attorney General and the Secretary of Health and Human Services shall jointly conduct a review of the processes used to register or modify a registration to conduct research with controlled substances under the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/801">21 U.S.C. 801 et seq.</external-xref>), including—</text><paragraph id="H4B14AE44FEFC4BC09DD0B088277C91EB"><enum>(1)</enum><text>an evaluation of the impacts of the amendments made by this Act on the risk of the diversion of controlled substances used in research and related public safety considerations; and</text></paragraph><paragraph id="H2180F848B31E461290A992D467AF28CB"><enum>(2)</enum><text>an identification of opportunities to reduce any unnecessary burden on persons seeking registration, potential redundancies, and inefficiencies in such processes, including—</text><subparagraph id="H72FC38DD0A4C4541A65CE1749228401E"><enum>(A)</enum><text>the process for obtaining a registration under section 303 of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/823">21 U.S.C. 823</external-xref>); and</text></subparagraph><subparagraph id="HD28F0405D192454D9820EE6FB030B747"><enum>(B)</enum><text>the process by which the Secretary reviews research protocols submitted with respect to such registration.</text></subparagraph></paragraph></subsection><subsection id="H3730771DD52640BBA0BC9F6404CC4566"><enum>(b)</enum><header>Guidance</header><text>Not later than 60 days after concluding the review described in subsection (a), the Attorney General and the Secretary shall, as appropriate, jointly issue guidance to registrants and potential registrants clarifying the process for registration.</text></subsection></section></legis-body></bill> 

